Hanmi Pharm (KRX:128940) swung to a net loss attributable to shareholders of the parent company of 1.996 trillion won in the fourth quarter of 2024 from a net income of 34.4 billion won a year earlier.
The company's sales declined 16.7% year over year to 351.6 billion won from 422.4 billion won, according to a Korea Exchange filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.